fluorobenzenes has been researched along with Innate Inflammatory Response in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.08) | 18.7374 |
| 1990's | 1 (2.08) | 18.2507 |
| 2000's | 20 (41.67) | 29.6817 |
| 2010's | 25 (52.08) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, LY; Liu, HJ; Liu, YN; Niu, HL; Shao, LM; Wang, J; Wang, K; Xue, DQ; Zheng, YL; Zou, AR | 1 |
| Amar, MJ; Baranova, IN; Bocharov, AV; Chen, Z; Eggerman, TL; Hu, X; Patterson, AP; Remaley, AT; Souza, ACP; Star, RA; Vaisman, BL; Vishnyakova, TG; Yuen, PST | 1 |
| Anthony, DC; Couch, Y; Howarth, C; Khrapitchev, AA; Martin, CJ; Raley, J; Sharp, T; Sibson, NR; Stratford, M | 1 |
| Aissouni, Y; Chalus, M; Courteix, C; Dupuis, A; Eschalier, A; Hernández, A; Marin, P; Pelissier, T; Pichon, X; Privat, AM; Wattiez, AS | 1 |
| Hübner, N; Kazdová, L; Kurtz, TW; Landa, V; Mancini, M; Mlejnek, P; Oliyarnyk, O; Pravenec, M; Saar, K; Schulz, H; Šilhavý, J; Šimáková, M; Škop, V; Zídek, V | 1 |
| Aakhus, S; Andreassen, J; Askevold, ET; Aukrust, P; Broch, K; Gjertsen, E; Godang, K; Gullestad, L; Smith, HJ; Stueflotten, W; Svendsmark, R; Ueland, T; Yndestad, A | 1 |
| Funderburg, NT; Hileman, CO; Longenecker, CT; McComsey, GA | 1 |
| Dostal, E; Gaspar, L; Goliasch, G; Hofbauer, SL; Huber, K; Kastl, SP; Katsaros, KM; Krychtiuk, KA; Maurer, G; Oravec, S; Pfaffenberger, S; Pongratz, T; Speidl, WS; Wojta, J; Wonnerth, A | 1 |
| Einvik, G; Hagve, TA; Høiseth, AD; Lehmann, S; Neukamm, A; Omland, T; Søyseth, V | 1 |
| Boolell, V; Calkin, AC; Chew, C; Cooper, ME; Giunti, S; Jandeleit-Dahm, KA; Rajaram, YS; Sheehy, KJ | 1 |
| Matsunaga, A; Miura, S; Nishikawa, H; Noda, K; Ogawa, M; Rainwater, DL; Saku, K; Shirai, K; Uehara, Y; Zhang, B | 1 |
| Gratsianskiĭ, NA; Iavelov, IS; Masenko, VP; Polenova, NV; Vaulin, NA | 1 |
| Fiebeler, A; Haller, H; Luft, FC; Menne, J; Mervaala, EM; Muller, DN; Park, JK | 1 |
| Després, JP | 1 |
| Davidson, MH; Friedewald, VE; Ridker, PM; Roberts, WC; Willerson, JT | 1 |
| Fabbri, G; Maggioni, AP | 1 |
| Kones, R | 2 |
| Belenkov, YN; Ezhov, MV; Gabrusenko, SA; Kuharchuk, VV; Masenko, VP; Semenova, AE; Sergienko, IV | 1 |
| Andreou, I; Dimopoulos, MA; Gounari, P; Miliou, A; Papadimitriou, CA; Papageorgiou, N; Siasos, G; Stefanadis, C; Tentolouris, C; Tousoulis, D; Zisimos, K | 1 |
| Bartholomew, JR; Perez, A | 1 |
| Ridker, PM | 1 |
| Bergheanu, SC; Dallinga-Thie, GM; Hattori, H; Karalis, IK; Liem, AH; van Tol, A; Wolterbeek, R; Wouter Jukema, J | 1 |
| Melfi, R; Nusca, A; Patti, G; Sciascio, GD | 1 |
| Andreou, I; Dimopoulos, MA; Miliou, A; Papadimitriou, CA; Papageorgiou, N; Siasos, G; Stefanadis, C; Tentolouris, C; Tousoulis, D; Tsiatas, M | 1 |
| Brookhart, MA; Glynn, RJ; Ridker, PM; Solomon, DH | 1 |
| Bi, H; Chen, WA; Daugherty, A; Hong, B; Luo, Y; Wang, JA; Wang, Y; Xie, X; Zhang, S | 1 |
| Agouridis, AP; Dimitriou, AA; Elisaf, MS; Filippatos, TD; Mikhailidis, DP; Tellis, CC; Tselepis, AD; Tsimihodimos, V | 1 |
| Gierman, LM; Huizinga, TW; Kleemann, R; Kloppenburg, M; Kooistra, T; Koudijs, A; Stojanovic-Susulic, V; Stoop, R; van der Ham, F; van Osch, GJ; Wielinga, PY; Zuurmond, AM | 1 |
| Belch, JJ; Kennedy, G; Khan, F; Kumar, P; Pullar, T | 1 |
| Cho, BH; Im, SY; Jin, ZW; Jung, SW; Kim, HK; Lee, CH; Lee, HK; Shin, SJ | 1 |
| Aukrust, P; Bottazzi, B; Cuccovillo, I; Gullestad, L; Latini, R; Lucci, D; Mantovani, A; Masson, S; Masuda, N; Nymo, SH; Sudo, Y; Tavazzi, L; Tognoni, G; Ueland, T; Vårdal, M; Wikstrand, J | 1 |
| Capecchi, PL; Capperucci, C; Ferrata, P; Frediani, B; Galeazzi, M; Laghi-Pasini, F; Lazzerini, PE; Niccolini, S; Spreafico, A | 1 |
| Diaz, JA; Hawley, AE; Lawrence, DA; Myers, DD; Patterson, KA; Wakefield, TW; Wrobleski, SK; Zhang, X | 1 |
| Iino, K; Ishida, M; Ito, H; Kosaka, T; Koyama, T; Nobori, K; Oguma, Y; Terata, Y; Watanabe, H; Yamazaki, D | 1 |
| Bernini, F; Catapano, AL | 1 |
| Baldasseroni, S; Fabbri, G; Maggioni, AP | 1 |
| Balakhonova, TV; Ezhov, MV; Masenko, VP; Naumov, VG; Pogorelova, OA; Samoĭlenko, EIu; Sergienko, IV; Sumarokov, AB; Tkachev, GA | 1 |
| Abbate, M; Banfi, C; Bellosta, S; Brioschi, M; Canavesi, M; Gelosa, P; Gianella, A; Guerrini, U; Mussoni, L; Nobili, E; Remuzzi, G; Rottoli, D; Sironi, L; Tremoli, E; Zoja, C | 1 |
| García-Moll, X | 1 |
| Alvarez-Aguilar, C; Gómez-García, A; Martínez Torres, G; Ortega-Pierres, LE; Rodríguez-Ayala, E | 1 |
| Jilma, B; Müller, M; Schmidt, WM; Spiel, AO; Wolzt, M | 1 |
| Ahmadi, S; Brockhaus, J; Brune, K; Fritschy, JM; Hess, A; Hösl, K; Knabl, J; Möhler, H; Reinold, H; Rudolph, U; Sergejeva, M; Witschi, R; Zeilhofer, HU; Zeilhofer, UB | 1 |
| Cottin, Y; Delemasure, S; Duvillard, L; Guilland, JC; Korandji, C; Lauzier, B; Rochette, L; Segueira-Le Grand, A; Sicard, P; Vergely, C; Zeller, M | 1 |
| Orr, JD | 1 |
| Firbas, C; Jilma, B; Leitner, JM; Mayr, FB; Sieghart, W; Spiel, AO | 1 |
| Branchek, TA; Calligaro, DO; Flaugh, ME; Gilbert, PJ; Johnson, KW; Kiefer, AD; Mancuso, V; Nelson, DL; Phebus, LA; Van Belle, K; Zgombick, JM | 1 |
| DiSaia, PJ; Morrow, MH; Nalick, RH; Rea, TH | 1 |
7 review(s) available for fluorobenzenes and Innate Inflammatory Response
| Article | Year |
|---|---|
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Evidence-Based Medicine; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Kidney Failure, Chronic; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Topics: Angina, Unstable; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome | 2009 |
Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers, Pharmacological; Confidence Intervals; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Kidney Diseases; Multivariate Analysis; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2010 |
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2010 |
[Rosuvastatin: pharmacologic features].
Topics: Animals; Arteriosclerosis; Biotransformation; Cholesterol; Drug Interactions; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2003 |
[Ongoing trials and future prospects].
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Fluorobenzenes; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
Statins in the spectrum of neurologic disease.
Topics: Alzheimer Disease; Animals; Atherosclerosis; Cardiovascular Diseases; Diabetic Neuropathies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Multiple Sclerosis; Nervous System Diseases; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Pyrimidines; Reactive Oxygen Species; Rosuvastatin Calcium; Stroke; Sulfonamides | 2008 |
14 trial(s) available for fluorobenzenes and Innate Inflammatory Response
| Article | Year |
|---|---|
The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Cholesterol, LDL; Extracellular Matrix; Female; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial.
Topics: Adult; AIDS-Associated Nephropathy; Anti-Retroviral Agents; Biomarkers; Cystatin C; Female; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney; Kidney Function Tests; Male; Middle Aged; Placebos; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial.
Topics: Aged; Biomarkers; C-Reactive Protein; Double-Blind Method; Endothelium, Vascular; Female; Fluorobenzenes; Forced Expiratory Volume; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Lung; Male; Pulmonary Disease, Chronic Obstructive; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vital Capacity | 2015 |
[Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
Topics: Aged; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lipids; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study.
Topics: Aged; Allopurinol; Biomarkers; Cholesterol; Cholesterol, LDL; Chronic Disease; Female; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Peroxidase; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2010 |
Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Carrier Proteins; Dose-Response Relationship, Drug; Enzymes; Female; Fluorobenzenes; Heptanoic Acids; Humans; Inflammation; Lipid Metabolism; Lipoproteins; Male; Maximum Tolerated Dose; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2010 |
Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress.
Topics: AC133 Antigen; Aged; Allopurinol; Antigens, CD; Antigens, CD34; Endothelial Cells; Enzyme Inhibitors; Female; Fluorobenzenes; Glycoproteins; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Peptides; Peroxidase; Pyrimidines; Rosuvastatin Calcium; Stem Cells; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2; Xanthine Oxidase | 2011 |
Effect of rosuvastatin on hemoglobin levels in patients with anemia and low-grade inflammation: a post hoc analysis of the JUPITER trial.
Topics: Aged; Anemia; Double-Blind Method; Female; Fluorobenzenes; Hemoglobins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Aryldialkylphosphatase; C-Reactive Protein; Dinoprost; Drug Combinations; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Inflammation; Lipids; Male; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Disease Progression; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Scotland; Sulfonamides; Treatment Outcome | 2012 |
Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.
Topics: Aged; C-Reactive Protein; Chronic Disease; Double-Blind Method; Female; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Serum Amyloid P-Component; Sulfonamides | 2012 |
Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Serum Amyloid P-Component; Sulfonamides; Tumor Necrosis Factor-alpha | 2013 |
In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model.
Topics: Cross-Over Studies; Double-Blind Method; Fluorobenzenes; Gene Expression; Humans; Inflammation; Leukocytes; Male; Placebos; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation.
Topics: Adult; Cell Count; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Endothelial Cells; Flow Cytometry; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipopolysaccharides; Male; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Stem Cells; Sulfonamides; Vascular Endothelial Growth Factor A | 2008 |
27 other study(ies) available for fluorobenzenes and Innate Inflammatory Response
| Article | Year |
|---|---|
Inhibition of Nav1.7 channel by a novel blocker QLS-81 for alleviation of neuropathic pain.
Topics: Action Potentials; Analgesics; Animals; Fluorobenzenes; Formaldehyde; Ganglia, Spinal; Guinea Pigs; HEK293 Cells; Humans; Inflammation; Male; Mice, Inbred C57BL; NAV1.7 Voltage-Gated Sodium Channel; Neuralgia; Neurons; Spinal Nerves; Voltage-Gated Sodium Channel Blockers | 2021 |
Human SR-BII mediates SAA uptake and contributes to SAA pro-inflammatory signaling in vitro and in vivo.
Topics: Animals; Biological Transport; Fluorescent Dyes; Fluorobenzenes; Gene Expression Regulation; HEK293 Cells; HeLa Cells; Humans; Inflammation; Kidney; Liver; Lysosomal Membrane Proteins; MAP Kinase Kinase 4; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Receptors, Scavenger; Serum Amyloid A Protein; Signal Transduction; Transfection; Transgenes | 2017 |
Systemic inflammation alters central 5-HT function as determined by pharmacological MRI.
Topics: Animals; Autoradiography; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Fenfluramine; Fluorobenzenes; Image Processing, Computer-Assisted; Inflammation; Laser-Doppler Flowmetry; Magnetic Resonance Imaging; Male; Microdialysis; Piperidines; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists | 2013 |
Disruption of 5-HT2A receptor-PDZ protein interactions alleviates mechanical hypersensitivity in carrageenan-induced inflammation in rats.
Topics: Animals; Bicuculline; Carrageenan; Disks Large Homolog 4 Protein; Fluorobenzenes; Fluoxetine; Hyperalgesia; Inflammation; Injections; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Pain; Peptides; Piperidines; Posterior Horn Cells; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists | 2013 |
Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels.
Topics: Animals; Anti-Inflammatory Agents; C-Reactive Protein; Disease Models, Animal; Fluorobenzenes; Gene Expression Regulation; Humans; Inflammation; Inflammation Mediators; Interleukin-6; Liver; Male; Myocytes, Cardiac; Oxidative Stress; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Transgenic; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha | 2014 |
Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease.
Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Female; Fluorobenzenes; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Humans; Inflammation; Interleukin-10; Lipids; Lipoproteins, HDL; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Monocytes; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Benzimidazoles; Biphenyl Compounds; Blood Vessels; Diabetes Mellitus; Disease Models, Animal; Fluorobenzenes; Glycation End Products, Advanced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tetrazoles | 2008 |
Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: the ROSARY Study.
Topics: Apolipoproteins; Biomarkers; Cholesterol; Cholesterol, HDL; Coronary Disease; Electrophoresis, Capillary; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Inflammation; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2009 |
Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Topics: Albuminuria; Angiotensin II; Animals; Blood Pressure; Collagen Type IV; Disease Models, Animal; Dose-Response Relationship, Drug; Fibronectins; Fluorescent Antibody Technique, Indirect; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunohistochemistry; Inflammation; Intercellular Adhesion Molecule-1; Kidney; Kidney Cortex; Kidney Medulla; Male; Monocytes; Necrosis; Neutrophil Infiltration; Nitric Oxide Synthase Type II; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Rosuvastatin Calcium; Sulfonamides | 2009 |
Bringing JUPITER down to earth.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Fluorobenzenes; Global Health; Health Services Needs and Demand; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Primary Prevention; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides | 2009 |
The editor's roundtable: the JUPITER trial--initial results and clinical implications.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients.
Topics: Angioplasty, Balloon, Coronary; C-Reactive Protein; Coronary Artery Disease; Female; Fibroblast Growth Factor 2; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Myocardial Revascularization; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Rosuvastatin Calcium; Sulfonamides; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2009 |
Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed.
Topics: Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Confidence Intervals; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Venous Thromboembolism | 2010 |
Statin therapy for elevated hsCRP: what are the public health implications?
Topics: Anticholesteremic Agents; C-Reactive Protein; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Public Health; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; United States | 2010 |
Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.
Topics: Angiotensin II; Animal Feed; Animals; Anti-Inflammatory Agents; Aorta; Aortic Aneurysm, Abdominal; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; Fluorobenzenes; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2011 |
Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice.
Topics: Animals; Body Weight; C-Reactive Protein; Cytokines; Diet, High-Fat; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation; Insulin; Male; Mice; Mice, Transgenic; Obesity; Osteoarthritis; Pyrimidines; Rosiglitazone; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones | 2012 |
Glutamine suppresses dinitrophenol fluorobenzene-induced allergic contact dermatitis and itching: inhibition of contact dermatitis by glutamine.
Topics: Animals; Anti-Inflammatory Agents; Cytoplasm; Dermatitis, Allergic Contact; Dinitrophenols; Ear; Female; Fluorobenzenes; Glutamine; Immunoblotting; Inflammation; Mice; Mice, Inbred C57BL; Phospholipases A2; Phosphorylation; Pruritus; RNA Interference | 2012 |
Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells.
Topics: Aged; Bone Resorption; Cell Proliferation; Cell Survival; Cells, Cultured; Culture Media; Diterpenes; Farnesol; Femur Head; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-1beta; Interleukin-6; Mevalonic Acid; Middle Aged; Osteoblasts; Osteoporosis; Osteoprotegerin; Pyrimidines; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Terpenes | 2013 |
Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects.
Topics: Animals; Apolipoproteins E; Cell Movement; Disease Models, Animal; Fluorobenzenes; Gene Deletion; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Interleukin-6; Male; Mice; Mice, Knockout; Neutrophils; P-Selectin; Pyrimidines; Rosuvastatin Calcium; Serpin E2; Sulfonamides; Thrombosis; Time Factors; Vena Cava, Inferior; Venous Thrombosis | 2013 |
[Effect of therapy with rosuvastatin on lipid spectrum, factors of inflammation and endothelial function in patients with ischemic heart disease].
Topics: Biomarkers; Brachial Artery; C-Reactive Protein; Endothelium, Vascular; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Doppler; Vasodilation | 2006 |
Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats.
Topics: Actins; Animals; Blood Pressure; Blotting, Western; Collagen; Disease Progression; Fibrinogen; Fibrinolysin; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microscopy, Electron; Plasminogen Activator Inhibitor 1; Plasminogen Activators; Podocytes; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides | 2007 |
[Inflammation, atherosclerosis, classic cardiovascular risk factors, biostatistics, clinical significance. Where are we?].
Topics: Acute Coronary Syndrome; Atherosclerosis; Biometry; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Inflammation; Metformin; Oxidative Stress; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha | 2007 |
[Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia].
Topics: Analysis of Variance; Dyslipidemias; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Inflammation; Interleukin-6; Metformin; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha | 2007 |
Reversal of pathological pain through specific spinal GABAA receptor subtypes.
Topics: Analgesics; Animals; Brain; Capsaicin; Chronic Disease; Diazepam; Disease Models, Animal; Fluorobenzenes; Formaldehyde; Ganglia, Spinal; Hot Temperature; Inflammation; Male; Mice; Neurons; Organ Specificity; Pain; Protein Isoforms; Protein Subunits; Rats; Rats, Wistar; Receptors, GABA-A; Spinal Cord; Triazoles | 2008 |
Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Arginine; Blood Pressure; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-4; Male; NADPH Oxidases; Oxidative Stress; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reactive Oxygen Species; Rosuvastatin Calcium; Sulfonamides | 2008 |
Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.
Topics: Animals; Brain; Carbazoles; Disease Models, Animal; Dura Mater; Fluorobenzenes; Humans; Inflammation; Male; Migraine Disorders; Protein Binding; Rats; Rats, Inbred F344; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Recombinant Proteins; Serotonin Receptor Agonists | 1997 |
Immunologic response in gynecologic malignancy as demonstrated by the delayed hypersensitivity reaction: clinical correlations.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antigens; Carcinoma in Situ; Carcinoma, Squamous Cell; Croton Oil; Fallopian Tube Neoplasms; Female; Fluorobenzenes; Genital Neoplasms, Female; Humans; Hypersensitivity, Delayed; Immunity, Cellular; Inflammation; Leprosy; Middle Aged; Nitro Compounds; Ovarian Neoplasms; Pilot Projects; Pregnancy; Skin Diseases; Trophoblastic Neoplasms; Uterine Cervical Diseases; Uterine Cervical Neoplasms; Uterine Neoplasms; Vulvar Neoplasms | 1974 |